Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 154   

Articles published

NVS 76.11 -0.73 (-0.95%)
price chart
Novartis AG (ADR) Entresto Clinches EU approval
Novartis Pharmaceuticals UK's Chief Scientific Officer, Dimitrios Georgiopoulos, says, “Heart failure is a life-threatening condition that leaves a major impact on patients and their carers.
Novartis Gets EU Approval for Cardiovascular Drug Entresto  Zacks.com
Trade of the Day: It's Not Too Late to Short NVS Stock
Novartis AG (ADR) (NVS) - I last featured NVS stock as the Trade of the Day on Oct. 1, recommending traders sell shares short at $95 with a downside target of $85.
UBS Downgrades Novartis AG (ADR) to Neutral
In a different note, On Mar 29, 2016, Citigroup said it Downgrades its rating on Novartis AG (ADR). The shares have been rated 'Neutral' by the firm.
Leerink Swann Downgrades Novartis AG (ADR) to Market Perform with Price Target ...
Brokerage firm Leerink Swann Downgrades its rating on Novartis AG (ADR)(NYSE:NVS). In a research note issued to the investors, the brokerage major Lowers the price-target to $85.00 per share.
Morning Watch List: Avis Budget Group, Inc. (NASDAQ:CAR), Ariad ...  Benchmark Monitor
Here's Why Novartis AG (ADR) Fared Better Than Others
Novartis AG ADR (NYSE:NVS) has signed three deals to expand its reach in the immune-oncology market. On Wednesday, Novartis announced that it had acquired Admune Therapeutics, a cancer drug maker.
Novartis (NVS) Strengthens It's Pipeline With Admune Therapeutics & XOMA  CNA Finance (press release)
HC Stocks Reports Analysis: Novartis AG (ADR) (NVS), Pfizer Inc. (PFE), Sanofi ...
Shares of Novartis AG (ADR) (NYSE:NVS) ended Thursday session in red amid volatile trading. The shares closed down -0.17 points or -0.22% at $76.81 with 2.26M shares getting traded.
No One Is Above The Law; Novartis AG (ADR) Has To Pay
Novartis AG (ADR) (NYSE:NVS) has concluded a settlement with the U.S. Justice Department regarding the drugmaker's paid rebate to the specialty pharmacies and reached an agreement to make certain changes on interactions with them.
Amgen, Inc. (NASDAQ:AMGN) Has Sued Novartis' AG (ADR) (NYSE:NVS) Sandoz Unit ...
Top-selling anti-inflammatory drug Enbrel from Amgen, Inc. (NASDAQ:AMGN) is facing steep competition from biosimilars that are hitting the market at a very rapid speed.
Amgen Inc to Face Off Pfizer & Novartis to Save Key Drugs  Bidness ETC
Novartis AG (ADR) And Roche May Have To Wait Longer For “Outcome-Based ...
The outcome-based drug pricing model is becoming a dream for Novartis AG (ADR) (NYSE:NVS) and Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY).
Trade of the Day: NVS Stock Not Making the Cut – Sell Now
Novartis AG (ADR) (NVS) - This company is a leading provider of pharmaceuticals, generic drugs and health care products for consumers and animals.